Vitamin D levels and menopause-related symptoms

Menopause

Volumn 21, Issue 11, 2014, Pages 1197-1203

  LeBlanc, Erin S ^a   Desai, Manisha ^b   Perrin, Nancy ^a   Wactawski Wende, Jean ^c   Manson, JoAnn E ^d   Cauley, Jane A ^f   Michael, Yvonne L ^e   Tang, Jean ^b   Womack, Catherine ^g   Song, Yiqing ^d   Johnson, Karen C ^g   O'Sullivan, Mary J ^h   Woods, Nancy ⁱ   Stefanick, Marcia L ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f DREXEL UNIVERSITY   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hot flashes; Menopause; Mood; Sleep; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; ESTROGEN; GESTAGEN; HYPNOTIC SEDATIVE AGENT; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VITAMIN D; 25-HYDROXYVITAMIN D; CALCIUM INTAKE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST TENDERNESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; EMOTION; ENERGY; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; MIGRAINE; MOOD DISORDER; NIGHT SWEAT; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTMENOPAUSE; PSYCHOLOGICAL WELL BEING; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SYMPTOM; TREMOR; VAGINAL DRYNESS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; BLOOD; CALCIUM INTAKE; CROSS-SECTIONAL STUDY; DIETARY SUPPLEMENT; EXERCISE; MENOPAUSE; METABOLISM; MIDDLE AGED; QUESTIONNAIRE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CALCIUM; CALCIUM, DIETARY; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; EMOTIONS; EXERCISE; FATIGUE; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; SLEEP WAKE DISORDERS; SURVEYS AND QUESTIONNAIRES; VITAMIN D; WOMEN'S HEALTH;

EID: 84918545965     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0000000000000238     Document Type: Article

References (54)

1. Simon JA, Reape KZ. Understanding the menopausal experiences of professional women. Menopause 2009;16:73-76.
2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
3. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358.
4. Li C, Wilawan K, Samsioe G, Lidfeldt J, Agardh CD, Nerbrand C. Health profile of middle-aged women: The Women's Health in the Lund Area (WHILA) study. Hum Reprod 2002;17:1379-1385.
5. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Vasomotor symptoms and well-being in the climacteric years. Maturitas 1996;23:293-299.
6. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
7. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105(pt 1):1063-1073.
8. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: A randomized controlled trial. JAMA 2011;305:267-274.
9. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: A longitudinal study. Menopause 2009;16:453-457.
10. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: A meta-analysis. J Gen Intern Med 2008;23: 1507-1513.
11. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-2244.
12. Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110(pt 1):230-240.
13. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: A community based prospective study. Maturitas 2002;42:195-200.
14. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: A multiethnic community study. Am J Public Health 2001;91:1435-1442.
15. Nelson HD, Haney E, Humphrey L, et al. Management of Menopause- Related Symptoms: Summary. Rockville, MD: Agency for Healthcare Research and Quality; 2005:1-6. Evidence Report/Technology Assessment 120.
16. National Institutes of Health. National Institutes of Health State-of-the- Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142(pt 1):1003-1013.
17. Park MK, Satoh N, Kumashiro M. Effects of menopausal hot flashes on mental workload. Ind Health 2011;49:566-574.
18. Geukes M, van Aalst MP, Nauta MC, Oosterhof H. The impact of menopausal symptoms on work ability. Menopause 2012;19:278-282.
19. Sarrel PM. Women, work, and menopause. Menopause 2012;19:250-252.
20. Conde DM, Pinto-Neto AM, Santos-Sa D, Costa-Paiva L, Martinez EZ. Factors associated with quality of life in a cohort of postmenopausal women. Gynecol Endocrinol 2006;22:441-446.
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
22. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
23. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
24. Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: A Swedish populationY based study. Menopause 2009;16: 1213-1217.
25. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
26. Heaney RP, Recker RR, Stegman MR, Moy AJ. Calcium absorption in women: relationships to calcium intake, estrogen status, and age. J Bone Miner Res 1989;4:469-475.
27. Arvold DS, Odean MJ, Dornfeld MP, et al. Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: A randomized controlled trial. Endocr Pract 2009;15:203-212.
28. Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010;17: 946-954.
29. Khan QJ, Reddy PS, Kimler BF, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010;119:111-118.
30. Cass WA, Smith MP, Peters LE. Calcitriol protects against the dopamineand serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 2006;1074:261-271.
31. Rossmanith WG, Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol 2009;25:303-314.
32. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36:155-164.
33. Pinkerton JV, Zion AS. Vasomotor symptoms in menopause: where we've been and where we're going. J Womens Health (Larchmt) 2006;15:135-145.
34. Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int 1986;39:139-144.
35. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 2008; 264:599-609.
36. Lansdowne AT, Provost SC. Vitamin D3 enhances mood in healthy subjects during winter. Psychopharmacology (Berl) 1998;135:319-323.
37. Gloth FM III, Alam W, Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 1999;3:5-7.
38. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(suppl 9): S78-S86.
39. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(suppl 9):S87-S97.
40. Jackson RD, LaCroix AZ, Cauley JA, McGowan J. The Women's Health Initiative calcium vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(suppl 9):S98-S106.
41. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-683.
42. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696.
43. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008;100:1581-1591.
44. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-988.
45. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Base-line quality-oflife assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 1995;87:1372-1382.
46. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), 1: conceptual framework and item selection. Med Care 1992;30:473-483.
47. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res 1994;3:7-12.
48. Levine DW, Kripke DF, Kaplan RM, et al. Reliability and validity of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess 2003;15:137-148.
49. Millen AE, Wactawski-Wende J, Pettinger M, et al. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: The Women's Health Initiative calcium plus vitamin D clinical trial. Am J Clin Nutr 2010;91:1324-1335.
50. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr 1999;53:920-926.
51. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-693.
52. Patterson RE, Levy L, Tinker LF, Kristal AR. Evaluation of a simplified vitamin supplement inventory developed for the Women's Health Initiative. Public Health Nutr 1999;2:273-276.
53. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930.
54. Benjamini B, Hochner H. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.